Articles

New research reveals that brain metastases harbor distinct clinically actionable genetic alterations compared with primary tumors and extracranial metastases. Read More ›

Read More ›

DS-8201 yields exciting results in HER2-positive, TDM-1 resistant, or refractory metastatic disease, but providers should remain vigilant about the incidence of interstitial lung disease. Read More ›

With several new therapies on the horizon for HER2-positive metastatic breast cancer, tucatinib stands out for its notable activity in patients with brain metastases. Read More ›

Treatment options continue to emerge for patients with HER2-positive advanced breast cancer, with some generating more buzz than others. Read More ›

Should all patients with HER2-positive tumors between 1 cm and 2 cm receive neoadjuvant chemotherapy? Experts weigh in. Read More ›

A study of a large national database suggests that 31 to 60 days postsurgery is ideal. Read More ›

Central nervous system objective responses were observed in patients with HER2-positive metastatic breast cancer treated with neratinib in 3 separate clinical trials. Read More ›

After 7 years of follow-up, sustained progression-free survival and overall survival rates were seen with ibrutinib, as well as stable or improved complete response rates over time. Read More ›

informCLL registry analysis revealed that prognostic testing patterns in the real-world setting remain suboptimal despite inclusion in National Comprehensive Cancer Network and International Workshop on Chronic Lymphocytic Leukemia guidelines. Read More ›